Behavioural and neurobiological consequences of macrophage migration inhibitory factor gene deletion in mice

被引:22
|
作者
Bay-Richter, Cecilie [1 ]
Janelidze, Shorena [2 ]
Sauro, Analise [3 ]
Bucala, Richard [4 ]
Lipton, Jack [5 ]
Deierborg, Tomas [6 ]
Brundin, Lena [3 ,7 ]
机构
[1] Aarhus Univ, Dept Clin Med, Translat Neuropsychiat Unit, Risskov, Denmark
[2] Lund Univ, Dept Clin Sci, Clin Memory Res Unit, Malmo, Sweden
[3] Michigan State Univ, Dept Psychiat & Behav Med, Grand Rapids, MI USA
[4] Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA
[5] Michigan State Univ, Dept Translat Sci & Mol Med, Grand Rapids, MI USA
[6] Lund Univ, Dept Expt Med Sci, BMC, Expt Neuroinflammat Lab, Lund, Sweden
[7] Van Andel Res Inst, Lab Behav Med, Grand Rapids, MI USA
来源
JOURNAL OF NEUROINFLAMMATION | 2015年 / 12卷
基金
瑞典研究理事会;
关键词
Macrophage migration inhibitory factor; Depression; Cytokines; Dopamine; Inflammation; NECROSIS-FACTOR-ALPHA; MAJOR DEPRESSION; FACTOR MIF; INTERFERON-ALPHA; SOCIAL DEFEAT; GROWTH-FACTOR; UP-REGULATION; ANIMAL-MODEL; EXPRESSION; INFLAMMATION;
D O I
10.1186/s12974-015-0387-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Evidence from clinical studies and animal models show that inflammation can lead to the development of depression. Macrophage migration inhibitory factor (MIF) is an important multifunctional cytokine that is synthesized by several cell types in the brain. MIF can increase production of other cytokines, activates cyclooxygenase (COX)-2 and can counter-regulate anti-inflammatory effects of glucocorticoids. Increased plasma levels of MIF are associated with hypothalamic-pituitary-adrenal (HPA) axis dysregulation and depressive symptoms in patients. In contrast, MIF knockout (KO) mice have been found to exhibit increased depressive-like behaviour. The exact role for MIF in depression is therefore still controversial. To further understand the role of MIF in depression, we studied depressive-like behaviour in congenic male and female MIF KO mice and wild-type (WT) littermates and the associated neurobiological mechanisms underlying the behavioural outcome. Methods: MIF KO and WT mice were tested for spontaneous locomotor activity in the open-field test, anhedonia-like behaviour in the sucrose preference test (SPT), as well as behavioural despair in the forced swim test (FST) and tail suspension test (TST). Brain and serum levels of cytokines, the enzymes COX-2 and indoleamine-2,3-dioxygenase (IDO) and the glucocorticoid hormone corticosterone were measured by RT-qPCR and/or high-sensitivity electrochemiluminescence-based multiplex immunoassays. Monoamines and metabolites were examined using HPLC. Results: We found that MIF KO mice of both sexes displayed decreased depressive-like behaviour as measured in the FST. In the TST, a similar, but non-significant, trend was also found. IFN-gamma levels were decreased, and dopamine metabolism increased in MIF KO mice. Decreased brain IFN-gamma levels predicted higher striatal dopamine levels, and high dopamine levels in turn were associated with reduced depressive-like behaviour. In the SPT, there was a sex-specific discrepancy, where male MIF KO mice showed reduced anhedonia-like behaviour whereas female KO mice displayed increased anhedonia-like behaviour. Our results suggest that this relates to the increased corticosterone levels detected in female, but not male, MIF KO mice. Conclusions: Our findings support that MIF is involved in the generation of depressive-like symptoms, potentially by the effects of IFN-gamma on dopamine metabolism. Our data further suggests a sex-specific regulation of the involved mechanisms.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Behavioural and neurobiological consequences of macrophage migration inhibitory factor gene deletion in mice
    Cecilie Bay-Richter
    Shorena Janelidze
    Analise Sauro
    Richard Bucala
    Jack Lipton
    Tomas Deierborg
    Lena Brundin
    Journal of Neuroinflammation, 12
  • [2] Antidepressant effects of macrophage migration inhibitory factor gene deletion
    Bay-Richter, C.
    Janelidze, S.
    Bucala, R.
    Deierborg, T.
    Brundin, L.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 : 179 - 179
  • [3] DELETION OF MACROPHAGE MIGRATION INHIBITORY FACTOR REDUCES SEVERITY OF OSTEOARTHRITIS IN MICE
    Greene, M. A.
    Roland, A. L.
    Pritzker, L.
    Carlson, C. S.
    Bucala, R. J.
    Miller, R. A.
    Loeser, R. F., Jr.
    OSTEOARTHRITIS AND CARTILAGE, 2014, 22 : S58 - S59
  • [4] Reduced Osteoarthritis Severity in Aged Mice With Deletion of Macrophage Migration Inhibitory Factor
    Rowe, Meredith A.
    Harper, Lindsey R.
    McNulty, Margaret A.
    Lau, Anthony G.
    Carlson, Cathy S.
    Leng, Lin
    Bucala, Richard J.
    Miller, Richard A.
    Loeser, Richard F.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (02) : 352 - 361
  • [5] Deletion of macrophage migration inhibitory factor worsens stroke outcome in female mice
    Turtzo, L. Christine
    Li, Jun
    Persky, Rebecca
    Benashski, Sharon
    Weston, Gillian
    Bucala, Richard
    Venna, Venugopal Reddy
    McCullough, Louise D.
    NEUROBIOLOGY OF DISEASE, 2013, 54 : 421 - 431
  • [6] Deletion of macrophage migration inhibitory factor ameliorates inflammation in mice model severe acute pancreatitis
    Zhu, Changju
    Liu, Yanna
    Song, Yaodong
    Wang, Qiaofang
    Liu, Yanyan
    Yang, Shujun
    Li, Dejian
    Zhang, Yan
    Cheng, Bo
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 125
  • [7] Genetic deletion of macrophage migration inhibitory factor reduces oral carcinogenesis
    Oghumu, Steve
    Knobloch, Thomas
    Terrazas, Cesar
    Varikuti, Sanjay
    Bollinger, Claire
    Iwenofu, Hans
    Weghorst, Christopher
    Satoskar, Abhay
    CANCER RESEARCH, 2016, 76
  • [8] Macrophage migration inhibitory factor
    Leng, L
    Bucala, R
    CRITICAL CARE MEDICINE, 2005, 33 (12) : S475 - S477
  • [9] Macrophage migration inhibitory factor
    Lolis, E
    Bucala, R
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2003, 7 (02) : 153 - 164
  • [10] Macrophage migration inhibitory factor
    Baugh, JA
    Bucala, R
    CRITICAL CARE MEDICINE, 2002, 30 (01) : S27 - S35